Pharvaris N.V. (PHVS): Price and Financial Metrics


Pharvaris N.V. (PHVS): $9.46

0.04 (+0.42%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add PHVS to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

PHVS Stock Price Chart Interactive Chart >

Price chart for PHVS

PHVS Price/Volume Stats

Current price $9.46 52-week high $27.50
Prev. close $9.42 52-week low $1.77
Day low $8.88 Volume 38,175
Day high $9.58 Avg. volume 101,700
50-day MA $7.43 Dividend yield N/A
200-day MA $12.82 Market Cap 301.21M

Pharvaris N.V. (PHVS) Company Bio


Pharvaris B.V. operates as a clinical-stage company. The Company focuses on the discovery and development of novel oral B2-receptor antagonists for the treatment of patients. Pharvaris serves customers in the Netherlands and Switzerland.


PHVS Latest News Stream


Event/Time News Detail
Loading, please wait...

PHVS Latest Social Stream


Loading social stream, please wait...

View Full PHVS Social Stream

Latest PHVS News From Around the Web

Below are the latest news stories about PHARVARIS NV that investors may wish to consider to help them evaluate PHVS as an investment opportunity.

Pharvaris N.V.'s (NASDAQ:PHVS) largest shareholders are private equity firms with 44% ownership, institutions own 26%

To get a sense of who is truly in control of Pharvaris N.V. ( NASDAQ:PHVS ), it is important to understand the...

Yahoo | January 24, 2023

Pharvaris: Focused Pipeline On Hereditary Angioedema

Pharvaris (PHVS) is a company very focused on developing therapies for all sub-types of hereditary angioedema (HAE'). Their pipeline looks like this:

Pharvaris pipeline

Pharvaris pipeline (Pharvaris website)

Avisol Capital Partners on Seeking Alpha | January 13, 2023

Pharvaris (PHVS): Focused Pipeline On Hereditary Angioedema

Pharvaris has a pipeline fully focused on HAE and its molecule has a differentiated value proposition. Find out why PHVS stock is a Hold.

Seeking Alpha | January 13, 2023

Pharvaris Provides Regulatory, Clinical, and Corporate Updates

ZUG, Switzerland, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today provided business updates and company highlights. Business Updates and Company Highlights Meeting minutes from Type A meeting with U.S. Food and Drug Administration (FDA) received. Pharvaris will conduct a 26-week rodent toxicology study to resolve the clinical holds in the

Yahoo | January 9, 2023

Was anything positive for Pharvaris N.V. (PHVS) stock last session?

Pharvaris N.V. (NASDAQ:PHVS) marked $9.30 per share on Tuesday, up from a previous closing price of $7.59. While Pharvaris N.V. has overperformed by 22.53%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, PHVS fell by -38.29%, with highs and lows ranging from $27.50 to $1.77, whereas […]

US Post News | December 21, 2022

Read More 'PHVS' Stories Here

PHVS Price Returns

1-mo -15.23%
3-mo 88.22%
6-mo -56.69%
1-year -44.35%
3-year N/A
5-year N/A
YTD -15.91%
2022 -21.82%
2021 N/A
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7009 seconds.